Purinergic Signalling in Immune System Regulation in Health and Disease by Sévigny, Jean et al.
Editorial
Purinergic Signalling in Immune System Regulation in
Health and Disease
Jean Sévigny,1,2 Mireia Martín-Satué,3,4 and Jesús Pintor5
1De´partement de Microbiologie-Infectiologie et d’Immunologie, Faculte´ de Me´decine, Universite´ Laval, Que´bec City,
QC, Canada G1V 0A6
2Centre de Recherche du CHU de Que´bec, QC, Canada G1V 4G2
3Departament de Patologia i Terape`utica Experimental, Facultat de Medicina, Universitat de Barcelona,
08907 L’Hospitalet de Llobregat, Spain
4Institut d’Investigacio´ Biome`dica de Bellvitge, 08908 Barcelona, Spain
5Department of Biochemistry and Molecular Biology, Faculty of Optics, Universidad Complutense de Madrid, 28037 Madrid, Spain
Correspondence should be addressed to Jean Se´vigny; jean.sevigny@crchul.ulaval.ca,
Mireia Mart´ın-Satue´; martinsatue@ub.edu, and Jesu´s Pintor; jpintor@vet.ucm.es
Received 11 December 2014; Accepted 11 December 2014
Copyright © 2015 Jean Se´vigny et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The concept of a purinergic signalling system was first
proposed by Professor Geoffrey Burnstock over 30 years ago.
This includes the cellular responses to purine nucleotides,
such as ATP, and nucleosides, such as adenosine, that act
as extracellular messengers playing a role through specific
nucleotide and adenosine receptors in all systems. Indeed, in
addition to their role in cellular metabolism, nucleotides as
well as nucleosides are extracellular mediators that activate
biological responses in all cells. Cells subjected to activation
or shear or mechanical stress release nucleotides such as ATP,
ADP, UTP, and UDP in large amounts. All cells can release
nucleotides in a controlled fashion [1]. The mechanisms of
nucleotide release have been the focus of intense research
activities but are still not fully understood. While activated
platelets and neurons release nucleotides by exocytosis, neu-
trophils, and T lymphocytes use pannexin-1 hemichannels
for nucleotide efflux, some cells also constitutively release
nucleotides.
Under normal conditions, blood levels of nucleotides
are below 0.1𝜇M, the level resulting from cell release,
degradation by ectonucleotidases and reuptake of nucleotides
after dephosphorylation by these enzymes [2]. There are
many sources of extracellular nucleotides. In the circulatory
system, red blood cells are a major source of nucleotides.
The dense granules of the platelets contain a phenomenal
amount of ATP and ADP approaching 1M concentration
that are secreted by exocytosis during activation.Nucleotides,
primarily ATP, can be released by the endothelial cells and
the smooth muscles cells of vessel walls. Nucleotide release
can be triggered by shear stress, hypoxia and cell breakdown.
As cytosolic ATP concentration is about 5mM, rupture
of the plasma membrane causes an increase in nucleotide
concentrations near the injured cells. These mechanisms
represent only a few examples of nucleotide release. Cells thus
release large amounts of ATP, in a controlled manner but also
when a cell is injured or dies which is particularly relevant in
situation of inflammation and/or diseases.
Once released, nucleotides activate ubiquitously
expressed ligand-gated ionotropic P2X receptors (P2X1–
7) and G-protein-coupled metabotropic P2Y receptors
(P2Y
1,2,4,6,11–14) [1]. In addition, the cysteinyl-leukotriene
receptor-1 and receptor-2 (CysLT
1
and CysLT
2
) and GPR17
can also respond to nucleotides. P2 receptor subtypes differ
with respect to selectivity towards nucleotides. All P2X
receptors are activated by ATP, P2Y
2
by ATP and UTP,
P2Y
1
, P2Y
12
, and P2Y
13
by ADP, P2Y
4
by UTP, P2Y
6
by
UDP (in mouse also by UTP [3]), P2Y
11
by ATP > ADP,
and P2Y
14
by UDP-glucose. In addition, adenosine, which
results from the complete dephosphorylation of ATP and
ADP by ectonucleotidases, activates P1-type receptors, which
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divide into four types: A
1
, A
2A, A2B, and A3. These receptors
are widely distributed and their activation has already been
demonstrated to modulate a myriad of biological responses.
The responses induced by nucleotides can be modulated
by cell surface enzymes generically called ectonucleotidases.
Among them, the members of the ectonucleoside triphos-
phate diphosphohydrolase family (E-NTPDases) [4, 5]
which convert tri- and diphosphonucleosides (ATP, ADP)
to their monophosphate derivative (AMP). The latter
is further hydrolysed to adenosine by ecto-5󸀠-nucle-
otidase (CD73). Several other enzymes also modulate
nucleotide concentrations, namely, nucleotide pyrophospha-
tases/diphosphodiesterases and alkaline and acid phospha-
tases. P2 receptor signalling can also be influenced by
the ectokinases, that is, ectonucleotide diphosphokinases
and adenylate kinases, that interconvert and regenerate
nucleotides, respectively [2]. Hydrolysis thus switches off the
nucleotide signal and plays a role in adenosine formation.
These enzymes thus control relative concentrations of each
nucleotide and nucleoside and, accordingly, regulate their
effects.
Since its discovery, purinergic signalling has been shown
to mediate a wide range of functions in health and dis-
ease, important among them being immunomodulation and
inflammation. Recent advances have been made in therapies
using nucleotide-related drugs in a broad range of patho-
logical conditions such as acute and chronic inflammatory
diseases. In this special issue, which is dedicated to purinergic
signalling in immune system regulation in health and disease,
we present 9 research papers and 4 reviews. The papers deal
with the following topics.
By catalyzing the hydrolysis of extracellular AMP to
adenosine, ecto-5󸀠-nucleotidase/CD73 was shown to con-
trol vascular permeability and immune responses. By using
double knockout mice lacking CD73 and another AMP-
degrading enzyme, prostatic acid phosphatase (PAP), G. G.
Yegutkin et al. show that PAP may have a synergistic role
together with CD73 in the immune system by contributing to
the lymphoid purine homeostasis and balance of leukocyte
subpopulations in the lymph nodes and thymus. However,
the absence of PAP alone did not have any significant effects
outside the thymus.
S. D. S. Oliveira et al. show that schistosomiasis reduces
peritoneal macrophage P2X7 receptor signaling which corre-
late with increased levels of TGF-𝛽1 in infected mice as well
as with reduced cell surface expression of P2X7. The involve-
ment of P2 receptors in chemotactic responses of fibroblasts
in the context of regulation of inflammatory responses and
tissue damage repair is addressed by M. Pimentel-Santillana
et al. in a paper that demonstrates that Prostaglandin E
2
inhibits P2Y-dependent cell migration.
Data presented by L. Oliveira et al. with a rat model
suggest that restoration of neuromuscular transmission and
immune competence may be possible by targeting common
adenosine deficits in patients with autoimmune myasthenia
gravis. In another paper, C. Vieira at al. show that postin-
flammatory ileitis suppresses adenosine neuromodulatory
control leading to acceleration of the gastrointestinal transit,
which may last more than a week. In an attempt to identify
biomarkers for endometriosis, an inflammatory estrogen-
dependent complex disorder that is one of the principal
causes of infertility in women, L. Texido´ et al. demonstrate
the presence of ectonucleotidase activities in the contents of
endometriomas.
The contribution carried out by K. R. Higgins et al.
indicates that the activation of a P2Y
2
receptor present in a
human monocytic cell line (THP-1) is very efficient inducing
the chemokine CCL2.The effect carried out by the purinergic
agonists is as good as the one triggered by lipopolysaccharide.
Moreover, these researchers have found that polymorphisms
of the P2Y
2
receptors are important regarding the CCL2
secretion. In this sense, human macrophages expressing
312Ser-P2Y
2
displayed significant UTP-induced CCL2 secre-
tion above background compared to 312Arg-P2Y
2
expressing
macrophages.
Neuroinflammation in the central nervous system occur-
ring during pathologies such as amyotrophic lateral scle-
rosis and multiple sclerosis is a severe problem associated
with those pathologies. S. Amadio et al. studied the role
of P2Y
12
receptors in the neuroinflammatory condition,
mainly on ramified microglia and myelinated fibers from
primary organotypic cerebellar cultures or tissue slices from
rat striatum, cerebellum, and spinal cord from symptomatic
animals. These authors suggest that the modulation of P2Y
12
expression might play a dual role as analytic marker of
branched/surveillant microglia and demyelinating lesions
and also that potentially could be a predictive value under
neuroinflammatory conditions as those found in amy-
otrophic lateral sclerosis and multiple sclerosis.
Laser therapy, particularly low-level-laser therapy, is
being used with success as a complementary treatment for
inflammation and wound healing in the dermis. L. Wang
et al. present a paper dealing with the effects of red-laser
irradiation on extracellular ATP content of mast cells and
dorsal root ganglia neurons. In this sense, the authors show
that irradiation potentiates extracellular ATP presence in
mast cells by promotingATP synthesis and release, but on the
contrary laser attenuates extracellular ATP amounts of dorsal
root ganglia neurons by upregulating ecto-ATPase activity.
This issue also presents the following reviews.The review
of F. Pedata et al. covers the role of the adenosine receptor A
2A
in acute injury and neuroinflammation in brain ischemia.
A. Guzman-Aranguez et al. review purinergic receptors in
ocular inflammation pointing out to the use of purinergic
agonists and antagonists as possible therapeutic targets for
inflammatory eye disorders. In their review, P. J. Sa´ez et al.
focus on the effects of different cytokines on the intercellular
communication mediated by hemichannels and gap junction
channels in antigen-presenting cells and their impact on
purinergic signaling. Finally, A. R. Santiago et al. reviewed the
role of the nucleoside adenosine in microglial proliferation,
chemotaxis, and reactivity. The authors focused on the
adenosine A
2A receptor and discuss its role in Parkinson’s
and Alzheimer’s diseases as well as in glaucoma and diabetic
retinopathy.
Although there is still much to learn about the precise
role of the adenosine and P2 receptors in the immune system
and in inflammation, there is now wider acceptance that
Mediators of Inflammation 3
adenosine andnucleotides have a real and important function
in this regard. This timely collection of well-informed and
insightful articles summarises where we are now and points
the future directions we should take. As the purinergic field
is growing rapidly and it is getting increasingly demanding
to keep up with the literature, we hope that this special
issue will not only be useful from this point of view but
also will inspire new experiments that reveal further insights
regarding adenosine and nucleotides in all the aspects related
to inflammation and the immune system.
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